for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Chugai Pharmaceutical Co Ltd

4519.T

Latest Trade

9,845.00JPY

Change

-12.00(-0.12%)

Volume

436,600

Today's Range

9,778.00

 - 

9,915.00

52 Week Range

6,170.00

 - 

9,915.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
9,857.00
Open
9,801.00
Volume
436,600
3M AVG Volume
14.28
Today's High
9,915.00
Today's Low
9,778.00
52 Week High
9,915.00
52 Week Low
6,170.00
Shares Out (MIL)
547.46
Market Cap (MIL)
5,510,108.00
Forward P/E
35.61
Dividend (Yield %)
0.90

Next Event

Full Year 2019 Chugai Pharmaceutical Co Ltd Earnings Release

Latest Developments

More

Chugai Pharmaceutical Says Tecentriq Approved As Lung Cancer Treatment In Japan

Chugai Obtains Approval Of FoundationOne CDx Cancer Genomic Profile As A Companion Diagnostic For Rozlytrek

Alexion Opposes Claims Against Co Filed By Chugai Pharmaceutical

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Chugai Pharmaceutical Co Ltd

CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Domestic segment is engaged in the sale of pharmaceutical products manufactured by the Company through its nationwide appointed stores. This segment is also involved in the research, development, transportation and storage of pharmaceutical products, as well as the provision of literature research services for pharmaceutical information. The Overseas segment is engaged in the sale of its pharmaceutical products in oversea markets, such as Germany, the United Kingdom, France, Taiwan, China Mainland, Korea and the United States. This segment is also involved in the provision of pharmaceutical academic information, as well as the research, development and registration of pharmaceutical products.

Industry

Major Drugs

Contact Info

15F, Nihonbashi Mitsui Tower

2-1-1, Nihonbashi-Muro-machi

+81.3.32816611

https://www.chugai-pharm.co.jp/

Executive Leadership

Osamu Nagayama

Chairman of the Board, Representative Director

Tatsuro Kosaka

President, Chief Executive Officer, Representative Director

Motoo Ueno

Vice Chairman of the Board, Representative Director

Toshiaki Itagaki

Chief Financial Officer, Senior Executive Officer, Director of Finance & Accounting, Senior Manager of Finance

Junichi Ebihara

Senior Executive Officer, Director of Legal Affairs

Key Stats

2.73 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2016

0.5K

2017

0.5K

2018

0.6K

2019(E)

0.7K
EPS (JPY)

2016

98.120

2017

133.040

2018

169.080

2019(E)

276.796
Price To Earnings (TTM)
38.67
Price To Sales (TTM)
8.32
Price To Book (MRQ)
6.63
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
17.35
Return on Equity (TTM)
14.57

Latest News

Latest News

BRIEF-Chugai Pharmaceutical Says Tecentriq Approved As Lung Cancer Treatment In Japan

* CHUGAI PHARMACEUTICAL - TECENTRIQ RECEIVES APPROVAL FOR ADDITIONAL INDICATION OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER FROM JAPAN'S MHLW

BRIEF-Chugai Obtains Approval Of FoundationOne CDx Cancer Genomic Profile As A Companion Diagnostic For Rozlytrek

* CHUGAI PHARMACEUTICAL - CHUGAI OBTAINS APPROVAL OF FOUNDATIONONE CDX CANCER GENOMIC PROFILE AS A COMPANION DIAGNOSTIC FOR ROZLYTREK Source text for Eikon: Further company coverage:

BRIEF-Chugai Pharmaceutical To Invest 25 Bln Yen Into A Singapore Research Center By 2021-Nikkei

* CHUGAI PHARMACEUTICAL LOOKS TO INVEST SOME 25 BILLION YEN INTO A SINGAPORE RESEARCH CENTER FOR BIOPHARMACEUTICALS BY 2021 - NIKKEI Source text :(s.nikkei.com/2CitZyn) Further company coverage: (bangalore.newsroom@thomsonreuters.com)

BRIEF-Chugai Pharmaceutical says change of chief executive officer

* Says it names current president and chief operating officer Tatsuro Kosaka as chief executive officer and president, effective late March 2018

BRIEF-R&I affirms Chugai Pharmaceutical's rating at "AA-" and says stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-" -R&I

Roche's Chugai transfers rights of 13 Long-Term Listed Products to Taiyo

Chugai Pharmaceuticals, a Japan-based Roche subsidiary, said on Tuesday it has agreed to transfer the marketing and manufacturing right of 13 long-term listed products to Taiyo Holdings' Taiyo Pharma.

BRIEF-Marketing and manufacturing right transfer of 13 long-term listed products from Chugai Pharmaceutical to Taiyo Pharma

* Says it and TAIYO HOLDINGS CO LTD announced today that they have entered into an agreement, under which the co and F. Hoffmann-La Roche, Ltd. will transfer the marketing authorizations, including marketing and manufacturing rights, of 13 long-term listed products manufactured...

BRIEF-Chugai Pharma considering selling production rights of some medications to Taiyo - Nikkei

* Chugai Pharma considering selling production, sales rights of some 15 medications with expired patents to Taiyo Holdings for about 20 billion yen - Nikkei Source text : (http://s.nikkei.com/2iRwewI) Further company coverage:

BRIEF-Chugai Pharmaceutical aims to increase core oper profit to more than 100 bln Yen in year ending Dec. 2019 - Nikkei

* Chugai Pharmaceutical Co Ltd aims to increase its core operating profit to more than 100 billion yen ($920 million) in the year ending December 2019 - Nikkei Source text (http://s.nikkei.com/2x6fubs) Further company coverage:

BRIEF-Chugai Pharmaceutical sells trusted beneficial rights of property

* Says it has sold the trusted beneficial rights of Tokyo-based property on May 12

BRIEF- Baxalta files lawsuit against Chugai Pharmaceutical and Genentech

* Says Baxalta filed a lawsuit against the company and Genentech Inc., in U.S. on May 4

BRIEF-Chugai Pharmaceutical to retire treasury shares

* Says it will retire 123,000 shares (0.02 percent of outstanding) of its common stock on April 28

BRIEF-Chugai Pharmaceutical to issue 123,000 shares for 469.9 mln yen

* Says it plans to issue 123,000 shares for 469.9 million yen in total

BRIEF-Chugai, Berlin-Chemie Menarini set license agreement for PA799

* Roche's chugai and Berlin-Chemie Menarini Group announce global license agreement for an anti-cancer agent PA799 Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up